ovarian cancer – Discover Pharma

Welcome to Discover Pharma! Today is : August 12, 2026

ovarian cancer

Advanced Therapies,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Oncoinvent publishes Radspherin dosimetry data in Journal of Nuclear Medicine
Oncoinvent has published Phase 1 dosimetry data for Radspherin in [...]

August 12, 2026
Clinical & Regulatory,Medical devices,Pharmaceuticals and therapeutics,Research & Development
IOTA founder recognised for global impact on ovarian tumour diagnosis
The founder of the International Ovarian Tumor Analysis collaboration has [...]

July 24, 2026
Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer
Context Therapeutics has reported encouraging interim Phase 1 data for [...]

June 15, 2026
Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas
Oncoinvent to present 24-month Phase 1 ovarian cancer data for Radspherin at ESGO 2026
Oncoinvent will present final 24-month follow-up data from its Phase [...]

May 5, 2026
Advanced Therapies,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas
University of Minnesota investigators awarded $665,000 in ScaleReady G-Rex Grant funding
Three research teams to advance manufacturing and development of cell [...]

May 5, 2026

main menu

recent posts

get connected

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK